Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Intellia Therapeutics reported positive Phase 3 HAELO clinical data for lonvo-z in HAE, with results presented at EAACI and published in the New England Journal of Medicine. The company anticipates FDA acceptance of a BLA (Biologics License Application) for lonvo-z in the second half of 2026.